'Idiopathic pulmonary fibrosis' presentation slideshows

Interstitial lung disease: A clinical overview and general approach

Interstitial lung disease: A clinical overview and general approach. By Prof. Ramadan Nafae Professor and Head of Chest Department Zagazig , Faulty of Medicine. Items:. Definition Epidemiology Classification Pathogenesis Diagnosis Treatment Final comments. Items:. Definition

1.26k views • 74 slides

Interstitial lung disease: A clinical overview and general approach

Interstitial lung disease: A clinical overview and general approach. By Prof. Ramadan Nafae Professor and Head of Chest Department Zagazig , Faulty of Medicine. Items:. Definition Epidemiology Classification Pathogenesis Diagnosis Treatment Final comments. Items:. Definition

935 views • 74 slides

Ganesh Raghu, MD, FCCP, FACP

Ganesh Raghu, MD, FCCP, FACP. Professor of Medicine and Laboratory Medicine (Adjunct) University of Washington, Seattle, WA, USA Chief, Chest Clinic Director, Interstitial Lung Disease, Sarcoid and Pulmonary Fibrosis Program Medical Director, Lung Transplant Program

947 views • 66 slides

Diploma Course in COPD Management

802 views • 61 slides

Interstitial Lung Disease (From the GP Perspective) .

Interstitial Lung Disease (From the GP Perspective). Dr Nazia Chaudhuri. Consultant Respiratory Physician with specialist interest in ILD & Honorary Senior Lecturer. University Hospital of South Manchester/ University of Manchester. http://northwestipfmanchester.weebly.com.

589 views • 53 slides

Recently Completed Trials in IPF: What have we learned? Where do we go from here?

659 views • 43 slides

LUNG TRANSPLANTATION

LUNG TRANSPLANTATION. ISKANDER AL-GITHMI, M.D., FRCSC, FRCSC (Ts & CDs), FCCP. Assistant Professor of Surgery Division of Cardiothoracic Surgery King Abdulaziz University. History:

617 views • 41 slides

Fibrosi Polmonare Idiopatica (IPF): Problemi Diagnostici e Terapeutici Pneumo Trieste 2017

504 views • 41 slides

LUNG TRANSPLANTATION and PULMONARY FIBROSIS

LUNG TRANSPLANTATION and PULMONARY FIBROSIS. Maria L. Padilla, MD Associate Prof. of Medicine Director of ILD/IPF and Advanced Lung Disease Program MSSM/MSMC. Organ Transplantation. Lung Transplantation and IPF. Important Questions: What is it? Why? For Whom? When? How?

427 views • 25 slides

Idiopathic Pulmonary Fibrosis and Oxygen Therapy

Idiopathic Pulmonary Fibrosis and Oxygen Therapy. Louie Boitano, RCP Pulmonary Clinic University of Washington Medical Center. Effects of Idiopathic Pulmonary Fibrosis.

401 views • 11 slides

Anti-Idiopathic Pulmonary Fibrosis Drugs Market

A research report on the global anti-idiopathic pulmonary fibrosis drugs market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market. Furthermore, the report includes the trends and opportunity in different regions for a better understanding of readers that helps to analyze the potential of the market.

99 views • 9 slides

Idiopathic Pulmonary Fibrosis Treatment Market Seeking Growth from Emerging Study Drivers, Restraints and Forecast 2026

Lack of awareness and availability of proper treatment is expected to hinder the idiopathic pulmonary fibrosis market growth. According to National Center for Biotechnology Information (NCBI) 2017 report, 54% patients do not receive any antifibrotic treatment in Europe.

86 views • 8 slides

Laminar Growth to be Witnessed by Current Trend Of Idiopathic Pulmonary Fibrosis Treatment Market

Lack of awareness and availability of proper treatment is expected to hinder the idiopathic pulmonary fibrosis market growth. According to National Center for Biotechnology Information (NCBI) 2017 report, 54% patients do not receive any antifibrotic treatment in Europe.

82 views • 8 slides

PICO

PICO. P: 60 year old male with idiopathic pulmonary fibrosis I: addition of oral acetylcysteine to standard therapy C: standard therapy O: Mortality, 6 min walk test, dyspnea, exercise capacity, quality of life, safety and pulmonary function tests. Search Strategy.

629 views • 4 slides